TSE:BCT BriaCell Therapeutics (BCT) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free BCT Stock Alerts C$2.29 +0.15 (+7.01%) (As of 05/31/2024 ET) Add Compare Share Share Today's RangeC$2.18▼C$2.3750-Day RangeC$1.87▼C$3.9552-Week RangeC$1.77▼C$10.29Volume16,020 shsAverage Volume8,707 shsMarket CapitalizationC$41.86 millionP/E RatioN/ADividend Yield13.70%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarnings Get BriaCell Therapeutics alerts: Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About BriaCell TherapeuticsBriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Read More BCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCT Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive BCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today6/01/2024Next Earnings (Estimated)6/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:BCT CUSIPN/A CIKN/A Webwww.briacell.com Phone604-921-1810FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-12,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-206.01% Return on Assets-85.45% Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueC($0.50) per share Price / Book-4.58Miscellaneous Outstanding Shares18,280,000Free FloatN/AMarket CapC$41.86 million OptionableNot Optionable Beta1.80 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. William V. Williams M.D. (Age 69)CEO, President & Director Comp: $1.08MMr. Gadi Levin B.Com. (Age 51)C.A., CPA, M.B.A., CFO & Corporate Secretary Comp: $418.13kDr. Miguel A. Lopez-Lago Ph.D. (Age 55)Chief Scientific Officer Comp: $410.49kDr. Giuseppe Del Priore M.D. (Age 62)M.P.H., MPH, Chief Medical Officer Comp: $676.38kDr. Charles Louis Wiseman FACP (Age 78)M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board Comp: $331.17kKey CompetitorsOncolytics BiotechTSE:ONCScythian BiosciencesCVE:SCYB138267 (COM.TO)TSE:COMNovoheartCVE:NVHSernovaTSE:SVAView All Competitors BCT Stock Analysis - Frequently Asked Questions Should I buy or sell BriaCell Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCT shares. View BCT analyst ratings or view top-rated stocks. How have BCT shares performed in 2024? BriaCell Therapeutics' stock was trading at C$7.80 on January 1st, 2024. Since then, BCT shares have decreased by 70.6% and is now trading at C$2.29. View the best growth stocks for 2024 here. When is BriaCell Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our BCT earnings forecast. How were BriaCell Therapeutics' earnings last quarter? BriaCell Therapeutics Corp. (TSE:BCT) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.68. How do I buy shares of BriaCell Therapeutics? Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:BCT) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.